ID   NCC-OS1-X2-C1
AC   CVCL_VM08
SY   NCC-OS1-C1; NCCOS1X2C1
DR   cancercelllines; CVCL_VM08
DR   DepMap; ACH-002778
DR   Wikidata; Q95992540
RX   DOI=10.2198/jelectroph.65.1;
RX   PubMed=29943355;
WW   https://en.cellline.jp/product/ncc-os1-x2-c1/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Characteristics: Established from a second generation xenograft established by subcutaneous injection in female SCID mice.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 29 hours (PubMed=29943355).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His66Arg (c.197A>G) (p.Pro80Pro, c.240A>G); ClinVar=VCV000246117; Zygosity=Unspecified (DOI=10.2198/jelectroph.65.1).
CC   Omics: Deep proteome analysis.
CC   Derived from site: In situ; Bone, distal femur; UBERON=UBERON_0004406.
ST   Source(s): PubMed=29943355
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,10
ST   D16S539: 11
ST   D21S11: 30
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 30-01-24; Version: 10
//
RX   DOI=10.2198/jelectroph.65.1;
RA   Noguchi R., Yoshimatsu Y., Ono T., Sei A., Kondo T.;
RT   "Proteogenomic approach to drug targets in osteosarcomas with
RT   different original sites.";
RL   J. Electroph. 65:1-11(2021).
//
RX   PubMed=29943355; DOI=10.1007/s11626-018-0274-2;
RA   Kito F., Oyama R., Sakumoto M., Takahashi M., Shiozawa K., Qiao Z.-W.,
RA   Sakamoto H., Hirose T., Setsu N., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of novel patient-derived
RT   osteosarcoma xenograft and cell line.";
RL   In Vitro Cell. Dev. Biol. Anim. 54:528-536(2018).
//